In yesterday’s Wall Street session, Johnson & Johnson (NYSE:JNJ) shares traded at $154.64, up 0.23% from the previous session.
JNJ stock price is now 1.46% away from the 50-day moving average and -1.50% away from the 200-day moving average. The market capitalization of the company currently stands at $372.17B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $170, HSBC Securities recently Upgraded its rating from Hold to Buy for Johnson & Johnson (NYSE: JNJ). On December 13, 2023, Wells Fargo Downgraded its previous ‘Overweight’ rating to ‘Equal Weight’ on the stock reducing its target price from $170 to quote $163, while ‘UBS’ rates the stock as ‘Buy’
In other news, Broadhurst Vanessa, EVP, Global Corp Affairs sold 8,891 shares of the company’s stock on Mar 13 ’24. The stock was sold for $1,441,765 at an average price of $162.16. Upon completion of the transaction, the EVP, Global Corp Affairs now directly owns 15,043 shares in the company, valued at $2.33 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 16 ’24, 10% Owner JOHNSON & JOHNSON sold 3,725 shares of the business’s stock. A total of $96,142 was realized by selling the stock at an average price of $25.81. This leaves the insider owning 4,099,575 shares of the company worth $633.96 million. A total of 0.17% of the company’s stock is owned by insiders.
During the past 12 months, Johnson & Johnson has had a low of $143.13 and a high of $175.97. As of last week, the company has a debt-to-equity ratio of 0.48, a current ratio of 1.17, and a quick ratio of 0.94.
According to the Drug Manufacturers – General Company, earnings per share came in at 2.56, missing analysts’ expectations of 2.62 by -0.06. This compares to $0.16 EPS in the same period last year. The net profit margin was 19.51% and return on equity was 23.91% for JNJ. The company reported revenue of $21.38 billion for the quarter, compared to $20.89 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.34 percent. For the current quarter, analysts expect JNJ to generate $22.28B in revenue.
